Aadi Bioscience Inc., a clinical-stage biotechnology company based in Pacific Palisades, has announced the finish of a $23 million series A funding round.
The financing, announced last week, will help drive clinical research for its ABI-009 for advanced perivascular epithelioid cell tumors, a rare sarcoma. Other clinical programs for the MTOR inhibitor include those for pulmonary hypertension, early stage bladder cancer and pediatric cancer.
The financing round, which closed May 8, was led by Hong Kong-based Hermed Capital with participation from Celgene Corp. of New Jersey, Vivo Capital, Decheng Capital, the Helsinn Investment Fund and Star Summit Ventures.
Aadi Bioscience was founded in 2011 by Dr. Neil Desai, an inventor of Abraxane, acquired by Celgene. He is also a former senior vice president of Abraxis BioScience Inc., a Los Angeles company founded by L.A. billionaire Dr. Soon-Shiong, acquired by Celgene in 2010 for $2.9 billion.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- PeproMene Bio Receives $40 Million
- Eos Biosciences Wins Patent for Cancer Drug Delivery System
- Celgene is Investor Behind NantCell $30M
- Biotech Mogul Patrick Soon-Shiong to Launch Nant IPO
- Puma Biotechnology Added to Nasdaq Biotech Index
- New Beachhead for Biotech
- Cell Care Therapeutics Raises $4.3M to Develop Treatment for Eye Diseases
- Puma Biotechnology Stock Tumbles After Thumbs Down by Euro Drug Regulators